| Drug ID: | Drug11 |
|---|---|
| Drug Name: | Berberine |
| CID: | 2353 |
| DrugBank ID: | DB04115 |
| Modality: | Small Molecule |
| Groups: | experimental |
| US Approved: | NO |
| Other Approved: | NO |
| Identifier: | NCT02962245 |
| Molecular Formula: | C20H18NO4+ |
| Molecular Weight: | 336.4 g/mol |
| Isomeric SMILES: | COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OC |
| Synonyms: | berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin; Berberone; Benzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium, 5,6-dihydro-9,10-dimethoxy- |
| Phase 0: | 2 |
| Phase 1: | 4 |
| Phase 2: | 15 |
| Phase 3: | 15 |
| Phase 4: | 21 |
| Description: | An alkaloid from Hydrastis canadensis L., Berberidaceae. It is also found in many other plants. It is relatively toxic parenterally, but has been used orally for various parasitic and fungal infections and as antidiarrheal. [PubChem] |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt90 | 2353 | Berberine | 7124 | TNF | Rattus norvegicus (Norway rat) | 25600690 | Berberine inhibits the reaction [mercuric chloride results in increased expression of TNF protein] |
| dt91 | 2353 | Berberine | 7150 | TOP1 | Homo sapiens (human) | 23747414 | Berberine results in decreased activity of TOP1 protein |
| dt92 | 2353 | Berberine | 7153 | TOP2A | Homo sapiens (human) | 23747414 | TOP2A protein affects the susceptibility to berberine|top2a protein affects the reaction [berberine results in increased expression of H2AX protein modified form] |
| dt93 | 2353 | Berberine | 7157 | TP53 | Homo sapiens (human) | 26712469 | Berberine results in increased phosphorylation of and results in increased acetylation of TP53 protein|[berberine co-treated with niacinamide] results in increased expression of and results in increased acetylation of TP53 protein |
| dt94 | 2353 | Berberine | 7157 | TP53 | Homo sapiens (human) | 20656010 | Berberine results in increased expression of TP53 mrna|berberine results in increased expression of TP53 protein |
| dt95 | 2353 | Berberine | 7186 | TRAF2 | Mus musculus (house mouse) | 30240693 | Berberine inhibits the reaction [[lipopolysaccharide, escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TRAF2 protein]|berberine inhibits the reaction [[lipopolysaccharide, escherichia coli O111 B4 co-treated with TNF |
| dt96 | 2353 | Berberine | 6737 | TRIM21 | Homo sapiens (human) | 36822301 | Berberine promotes the reaction [IGF2BP3 protein binds to TRIM21 protein] |
| dt97 | 2353 | Berberine | 100131187 | TSTD1 | Homo sapiens (human) | 27311644 | Berberine results in increased expression of TSTD1 mRNA |
| dt98 | 2353 | Berberine | 7319 | UBE2A | Homo sapiens (human) | 27311644 | Berberine results in decreased expression of UBE2A mRNA |
| dt99 | 2353 | Berberine | 7320 | UBE2B | Homo sapiens (human) | 27311644 | Berberine results in decreased expression of UBE2B mRNA |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT02962245 | Efficacy of Treatment With Berberine to Maintain Remission in Ulcerative Colitis | PHASE4 | WITHDRAWN | Xijing Hospital of Digestive Diseases | Ulcerative Colitis | DRUG: berberine|DRUG: regular treatment | Details |
| ChiCTR2400083224 | A clinical trial to evaluate the relationship between nitric oxide content in type 3 natural lymphocytes and severity of enteritis and response to drug intervention in patients with inflammatory bowel disease | Not Available | Not Recruiting | Peking University Third Hospital | Inflammatory Bowel Disease | Trial group:Berberine hydrochloride tablets mesa… | Details |
| NCT02365480 | Berberine Chloride in Preventing Colorectal Cancer in Patients With Ulcerative Colitis in Remission | PHASE1 | COMPLETED | National Cancer Institute (NCI) | Ulcerative Colitis | DRUG: Berberine Chloride|OTHER: Laboratory Biomar… | Details |
| NCT04985968 | The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis | PHASE3 | TERMINATED | InDex Pharmaceuticals | Ulcerative Colitis | DRUG: Cobitolimod 250 mg|DRUG: Cobitolimod 500 mg… | Details |
| NCT06681181 | A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK4528287 in Healthy Participants | PHASE1 | RECRUITING | GlaxoSmithKline | Colitis, Ulcerative | DRUG: GSK4528287|DRUG: Placebo | Details |
| NCT05992142 | ChAracterizing the Remission Status in Patients With Ulcerative Colitis Treated by 5-ASA | PHASE4 | COMPLETED | Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW | Ulcerative Colitis | DRUG: 5-ASA | Details |
| NCT00787202 | A Study To Investigate The Safety And Efficacy Of CP- 690,550 In Patients With Moderate And Severe Ulcerative Colitis. | PHASE2 | COMPLETED | Pfizer | Ulcerative Colitis | DRUG: CP- 690 550|DRUG: CP- 690 550|DRUG: CP- 690… | Details |
| NCT06321887 | EffiCacy and sAfEty of Low doSe orAl iRon for Anaemia in IBD | PHASE3 | RECRUITING | Liverpool University Hospitals NHS Foundation Trust | Inflammatory Bowel Disease|Iron Deficiency Anemia | DRUG: Ferrous fumarate syrup 2.5ml/70mg (22.5mg e… | Details |
| NCT00207688 | A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients | None | COMPLETED | Janssen Research & Development, LLC | Ulcerative Colitis | DRUG: Infliximab 5 mg/kg|DRUG: Infliximab 10 mg/k… | Details |
| NCT04677179 | A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC) | PHASE2 | TERMINATED | Nektar Therapeutics | Colitis, Ulcerative | DRUG: LY3471851|DRUG: Placebo | Details |
| NCT02958865 | Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis | PHASE2 | COMPLETED | Pfizer | Ulcerative Colitis | DRUG: PF-06651600 or Placebo|DRUG: PF-06700841 or… | Details |
| NCT03943550 | Double-Blinded, Placebo-Controlled Phase 1b Study for Safety, PK, Efficacy, PD of RO7049665 in Participants With Ulcerative Colitis (UC) | PHASE1 | TERMINATED | Hoffmann-La Roche | Ulcerative Colitis | DRUG: RO7049665|DRUG: Placebo | Details |
| NCT02840721 | Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis. | PHASE2 | COMPLETED | Telavant, Inc. | Colitis, Ulcerative | DRUG: PF-06480605 | Details |
| NCT04133194 | Adherence of a 1.600 mg Single Tablet 5-ASA Treatment of Ulcerative Colitis | PHASE4 | RECRUITING | Flemming Bendtsen | Ulcerative Colitis | DRUG: Mesalazine|DRUG: Mesalazine | Details |
| NCT01465763 | A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis | PHASE3 | COMPLETED | Pfizer | Ulcerative Colitis | DRUG: tofacitinib|DRUG: Placebo | Details |
| NCT06636656 | A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis | PHASE2 | RECRUITING | Boehringer Ingelheim | Ulcerative Colitis | DRUG: BI 3032950 intravenous (Part A)|DRUG: BI 30… | Details |
| NCT04996797 | A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005) | PHASE2 | ACTIVE_NOT_RECRUITING | Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Ulcerative Colitis | DRUG: Tulisokibart|DEVICE: Companion Diagnostic (… | Details |
| NCT01458951 | A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis | PHASE3 | COMPLETED | Pfizer | Ulcerative Colitis | DRUG: tofacitinib|DRUG: Placebo | Details |
| NCT04499495 | Assessment of 5-Aminosalicylic Acid Prescription Patterns and Treatment Outcomes in Patients With Ulcerative Colitis in Korea | None | COMPLETED | Ferring Pharmaceuticals | Ulcerative Colitis | OTHER: PENTASA (mesalamine/ 5-Aminosalicylic acid… | Details |
| NCT01959282 | A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis | PHASE2 | COMPLETED | Janssen Research & Development, LLC | Colitis, Ulcerative | DRUG: Placebo|DRUG: JNJ-54781532 25 mg once daily… | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S01 | Anti-inflammatory | inflammatory | 5-Aminosalicylates (5-ASAs); corticosteroids | Crohn's disease and ulcerative colitis are the two main com… | Details |
| S06 | Anti-fibrosis | fibrosis; tissue remodelling | GS-5745; STNM01 | Tissue remodelling and destruction in patients with IBD is … | Details |
| S07 | Blockade of cytokine | Cytokine signalling | apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab | Various T-cell subsets, their differentiation pathways and … | Details |
Antinociceptive effect of berberine on visceral hypersensitivity in rats
PMID: 23901236
Year: 2013
Relationship Type:
Association
Score: 9.1
AIM: To assess the protective effect of berberine administration and the role of nitric oxide (NO) in visceral hypersensitivity. METHODS: Fifty male …
Evidence for the complementary and synergistic effects of the three-alkaloid co…
PMID: 20969848
Year: 2011
Relationship Type:
Treatment
Score: 9.1
Ulcerative colitis involves complicated etiology and presents diverse symptoms including intestine inflammation, bowel pain and diarrhea. Anti-inflam…
Colon-targeted self-assembled nanoparticles loaded with berberine double salt a…
PMID: 39509850
Year: 2025
Relationship Type:
Association
Score: 6.5
Berberine-loaded PLGA nanoparticles alleviate ulcerative colitis by targeting I…
PMID: 39448992
Year: 2024
Relationship Type:
Association
Score: 6.5
Efficacy and safety of berberine plus 5-ASA for ulcerative colitis: A systemati…
PMID: 39241013
Year: 2024
Relationship Type:
Association
Score: 6.5
Berberine and magnolol exert cooperative effects on ulcerative colitis in mice …
PMID: 39227962
Year: 2024
Relationship Type:
Association
Score: 6.5
Berberine alleviates ulcerative colitis by inhibiting inflammation through targ…
PMID: 39068762
Year: 2024
Relationship Type:
Association
Score: 6.5
Exploration of Berberine Against Ulcerative Colitis via TLR4/NF-κB/HIF-1α Pathw…
PMID: 39006190
Year: 2024
Relationship Type:
Mechanism
Score: 6.5
Berberine, a natural alkaloid: Advances in its pharmacological effects and mech…
PMID: 38880024
Year: 2024
Relationship Type:
Treatment
Score: 6.5
Exosomes derived from mesenchymal stem cells containing berberine for ulcerativ…
PMID: 38815372
Year: 2024
Relationship Type:
Treatment
Score: 6.5
Berberine: Potential preventive and therapeutic strategies for human colorectal…
PMID: 38742849
Year: 2024
Relationship Type:
Treatment
Score: 6.5
Mitigation of inflammatory bowel disease-related osteoporosis by oxyberberine: …
PMID: 38574627
Year: 2024
Relationship Type:
Mechanism
Score: 6.5
Combined ROS Responsive Polydopamine-Coated Berberine Nanoparticles Effective A…
PMID: 38348171
Year: 2024
Relationship Type:
Association
Score: 6.5
Berberine regulates intestinal microbiome and metabolism homeostasis to treat u…
PMID: 38184271
Year: 2024
Relationship Type:
Association
Score: 6.5
Exploring the Mechanism of Berberine Intervention in Ulcerative Colitis from th…
PMID: 34211579
Year: 2021
Relationship Type:
Mechanism
Score: 6.5
BACKGROUND: We established and evaluated a radiomics nomogram based on multislice computed tomography (MSCT) arterial phase contrast-enhanced images…
Berberine-Loaded Carboxylmethyl Chitosan Nanoparticles Ameliorate DSS-Induced C…
PMID: 33959013
Year: 2021
Relationship Type:
Treatment
Score: 6.5
Ustekinumab (STELARA), a human monoclonal antibody directed against IL-12 and IL-23, is FDA-approved to treat psoriasis, psoriatic arthritis, Crohn'…
Berberine in the treatment of ulcerative colitis: A possible pathway through Tu…
PMID: 33348308
Year: 2021
Relationship Type:
Treatment
Score: 6.5
Berberine improves colitis by triggering AhR activation by microbial tryptophan…
PMID: 33285228
Year: 2021
Relationship Type:
Association
Score: 6.5
BACKGROUND: Better patient knowledge on inflammatory bowel disease [IBD] could improve outcome and quality of life. The aim of this study was to ass…
Protective role of berberine on ulcerative colitis through modulating enteric g…
PMID: 32140391
Year: 2020
Relationship Type:
Treatment
Score: 6.5
Background: Fecal calprotectin (FC) and serum C-reactive protein (CRP) are biomarkers of disease activity in Crohn's disease (CD) and ulcerative col…
LC-MS-based metabolomics analysis of Berberine treatment in ulcerative colitis …
PMID: 31756623
Year: 2019
Relationship Type:
Treatment
Score: 6.5
Inflammatory bowel disease (IBD) is a chronic inflammatory disorder which affects the gastrointestinal tract. Many factors, such as genetics, stress…